High ferritin: when it means iron overload and what treatment trials showed

Your blood test came back with ferritin flagged high, and the first thing many people read online is "iron overload". Sometimes that is the answer. Often it is not, and the next step depends on which one it is.

This article covers what a high ferritin can mean, which test sorts the possibilities, and what treatment trials have shown in each case.

This material is for information only and does not replace a consultation with a doctor. Tests and treatment are decided together with a clinician who knows your situation.

What does ferritin actually measure?

Ferritin is the protein the body stores iron in, and a small amount of it circulates in the blood. A low ferritin reliably means low iron stores. A high ferritin is much less specific. The British Society for Haematology guideline lists iron overload alongside inflammation, liver disease, kidney disease, cancer and the metabolic syndrome as causes of a raised value. So the number alone does not tell you whether there is too much iron in the body.

How often is a high ferritin real iron overload?

There is no single figure, because it depends on who was counted.

• In a Canadian liver clinic that reviewed 482 people referred for high ferritin, HFE haemochromatosis made up 28–42% of diagnoses across subgroups. Among people who did not carry two copies of the main haemochromatosis variant and had ferritin above 1000 µg/L, 64% had no iron overload on liver biopsy.

• In 80 referred patients of Asian origin in Vancouver, iron overload was found in 4 (5%); a secondary cause, most often liver disease, was found in 49.

Both are referred hospital patients, not everyone with a high result. The American College of Gastroenterology guideline adds that in people without the high-risk HFE genotypes, fatty liver disease and alcohol-related liver disease are more common causes of high ferritin than haemochromatosis.

Which test sorts it out?

The usual next step is transferrin saturation: the share of the iron-carrying protein in blood that is loaded with iron. In the European (EASL, 2022) guideline, a provisional diagnosis of iron overload in people with two copies of the C282Y variant of the HFE gene rests on transferrin saturation above 45% with ferritin above 200 µg/L in women, or above 50% with ferritin above 300 µg/L in men and postmenopausal women. The ACG guideline (2019) suggests HFE genetic testing when transferrin saturation is 45% or higher and ferritin is raised.

A high ferritin with a normal transferrin saturation points the search towards inflammation, the liver and metabolism rather than towards inherited iron overload.

If the gene test is positive, how likely is disease?

Less likely than the word "hereditary" suggests. In the Melbourne Collaborative Cohort, which genotyped 31,192 adults of northern European origin aged 40–69, iron-overload-related disease was found in 28.4% of men and 1.2% of women who carried two C282Y copies. In the same cohort, people with two copies whose ferritin stayed below 1000 µg/L had rates of disease features similar to people without the variant.

Why 1000? In 182 US clinic patients with haemochromatosis, advanced fibrosis, counted in that study as bridging fibrosis or definite cirrhosis, was found in 1 of 93 people with ferritin below 1000 µg/L and in 39 of 89 above it. This was measured in people already sent for biopsy, not in the general population, so it is a threshold for deciding on further liver assessment, not a prediction for an individual.

What has treatment by blood removal shown?

In haemochromatosis. Regular removal of blood (venesection, also called phlebotomy) is first-line treatment in the guidelines. The ACG aims for ferritin of 50–100 µg/L; EASL aims for 50 µg/L during the initial phase, but not lower, to avoid causing iron deficiency, then 50–100 µg/L during maintenance.

What the evidence does not say matters here. A 2017 Cochrane review found no randomised trial showing that blood removal reduces death, cirrhosis or liver cancer in haemochromatosis, and its authors noted such a trial against no treatment is unlikely to be run. The support comes from observation: in a German cohort of 251 patients followed for about 14 years, survival in those without cirrhosis or diabetes at diagnosis matched that of the general population. A randomised trial in which participants did not know their group, Mi-Iron (104 people with two C282Y copies and ferritin 300–1000 µg/L), found that iron removal lowered a fatigue score by 6.3 points compared with a sham procedure; the physical and psychosocial parts of that score did not differ. It measured reported fatigue, not cirrhosis or survival.

When ferritin is high because of metabolism or fatty liver. Here the trials point the other way. In a randomised trial of 74 people with non-alcoholic fatty liver disease, six months of blood removal lowered ferritin but did not change liver fat, liver enzymes or insulin resistance compared with lifestyle advice alone. In a French randomised trial of 274 people with dysmetabolic iron overload, a year of blood removal aimed at keeping ferritin below 50 µg/L (the treated group finished at about 71 µg/L on average) did not improve fasting glucose or liver tests; fatigue was more common in the blood-removal group. EASL does not recommend blood removal for high ferritin linked to metabolic liver disease, and a 2023 international consensus classes iron depletion here as experimental, to be tested in trials; outside trials it allows it only for confirmed severe liver iron with steatohepatitis or significant fibrosis that has not responded to treatment.

What do these findings not mean?

A high ferritin is not a diagnosis, and it is not by itself a reason for blood removal. The gene variant is not a diagnosis either, especially in women. And the 1000 µg/L line describes risk in clinic patients, not a guarantee above or below it.

What to do with the number

The questions the guidelines ask next are simple: what is the transferrin saturation, are there signs of inflammation, what do the liver tests and liver imaging show, and how much alcohol is involved. A single high ferritin is usually discussed with a doctor together with these, and often repeated. If you want more context on reading ferritin next to other red-cell markers, see our article on small red blood cells with normal haemoglobin, and on fatty liver, hepatic steatosis: what is proven.

Sources

• Cullis JO et al. Investigation and management of a raised serum ferritin. Br J Haematol. 2018. PMID 29672840

• Wong K, Adams PC. The diversity of liver diseases among outpatient referrals for an elevated serum ferritin. Can J Gastroenterol. 2006. PMID 16858498

• Yenson PR et al. Hyperferritinemia in the Chinese and Asian community. Can J Gastroenterol. 2008. PMID 18209779

• EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022. PMID 35662478

• Kowdley KV et al. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol. 2019. PMID 31335359

• Allen KJ et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008. PMID 18199861

• Allen KJ et al. HFE Cys282Tyr homozygotes with serum ferritin below 1000 µg/L are at low risk of hemochromatosis. Hepatology. 2010. PMID 20583211

• Morrison ED et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003. PMID 12693884

• Buzzetti E et al. Interventions for hereditary haemochromatosis. Cochrane Database Syst Rev. 2017. PMID 28273330

• Niederau C et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996. PMID 8613000

• Ong SY et al. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron). Lancet Haematol. 2017. PMID 29195602

• Adams LA et al. The impact of phlebotomy in nonalcoholic fatty liver disease. Hepatology. 2015. PMID 25524401

• Lainé F et al. Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome. Hepatology. 2017. PMID 27685251

• Valenti L et al. Consensus statement on the definition and classification of metabolic hyperferritinaemia. Nat Rev Endocrinol. 2023. PMID 36805052